Table 3 Multivariate analyses of local progression-free survival (LPFS)
Hazard ratio | 95% confidence interval | p-value | |
|---|---|---|---|
Interval between initial tumor diagnosis and RT of MSCC (≤15 vs. > 15 months) | 0.87 | 0.74–1.03 | 0.12 |
Visceral metastases at the time of RT (no vs. yes) | 0.56 | 0.39–0.78 | < 0.001 |
Other bone metastases at the time of RT (no vs. yes) | 1.41 | 0.96–2.10 | 0.08 |
Type of primary tumor (breast cancer vs. prostate cancer vs. myeloma/lymphoma vs. lung cancer vs. unknown primary vs. renal cell carcinoma vs. colorectal cancer vs. other tumors) | 1.91 | 1.17–3.09 | 0.009 |
Time developing motor deficits prior to RT (1–7 vs. 8–14 vs. > 14 days) | 0.48 | 0.32–0.71 | < 0.001 |
Gait function prior to RT (not ambulatory vs. ambulatory) | 0.81 | 0.58–1.12 | 0.19 |
Number of vertebrae affected by MSCC (1–2 vs. 3–4 vs. ≥5) | 1.28 | 0.82–1.98 | 0.27 |
ECOG performance score (1–2 vs. 3 vs. 4) | 1.57 | 1.12–2.18 | 0.009 |